ClearPoint Neuro (CLPT) Liabilities and Shareholders Equity (2011 - 2026)

ClearPoint Neuro has disclosed Liabilities and Shareholders Equity across 16 years of filings, most recently posting $93.4 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $93.4 million, up 210.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $314.4 million (up 94.04% YoY), and the FY2025 annual result was $97.7 million, up 149.42% from the prior year.
• Liabilities and Shareholders Equity came in at $93.4 million for Q1 2026 at ClearPoint Neuro, down from $97.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $97.7 million in Q4 2025 to a low of $30.1 million in Q1 2025.
• The 5-year median for Liabilities and Shareholders Equity is $53.6 million (2024), against an average of $55.9 million.
• Across the five-year window, Liabilities and Shareholders Equity plunged 43.94% in 2025 and surged 210.66% in 2026, its largest moves.
• ClearPoint Neuro's Liabilities and Shareholders Equity stood at $55.5 million in 2022, then decreased by 23.12% to $42.7 million in 2023, then fell by 8.14% to $39.2 million in 2024, then surged by 149.42% to $97.7 million in 2025, then dropped by 4.43% to $93.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $93.4 million (Q1 2026), $97.7 million (Q4 2025), and $60.4 million (Q3 2025), per Business Quant data.